Sermorelin for Adult GHD: Off-Label Dosing Protocol, Evidence, and Clinical Guidance
Sermorelin acetate is a synthetic growth hormone-releasing hormone (GHRH) analog, chemically corresponding to the first 29 amino acids of human GHRH(1-44). It is not the same molecule as growth hormone (somatropin) itself, and it is not the same class as ghrelin-mimetic secretagogues like ipamorelin or MK-677. Under the brand name Geref Diagnostic, sermorelin received FDA approval decades ago solely as a diagnostic test for growth hormone deficiency (GHD) in children with short stature. That branded product was discontinued by its manufacturer in 2008. No sermorelin product currently holds FDA approval for treating GHD in adults or children; all therapeutic use in adults is off-label and depends on compounded preparations.
This article is written for adults who have been diagnosed with GHD, or are exploring the diagnosis, and are considering sermorelin as an alternative to recombinant human growth hormone. It describes what is established, what is plausible but unproven, and what remains genuinely uncertain. It is not a substitute for individualized care from an endocrinologist, and it does not recommend a specific dose for any individual reader.
Sermorelin acetate, a GHRH analog, was FDA-approved only as a diagnostic agent for pediatric GHD (Geref Diagnostic), and that product was discontinued in 2008; no sermorelin product currently holds FDA approval for adult GHD treatment. Adult use today comes entirely from compounding pharmacies and is prescribed off-label, an approach not endorsed by major adult GHD treatment guidelines, which favor recombinant human growth hormone (somatropin). Because sermorelin can only stimulate GH release if the pituitary retains functioning somatotroph cells, patients whose GHD stems from pituitary surgery, radiation, or large sellar tumors are biologically unlikely to respond to it.
At a Glance
- FDA status: Sermorelin is not FDA-approved for treating GHD in adults; all adult therapeutic use is off-label.
- Original approval: Geref Diagnostic was approved as a diagnostic agent for pediatric GHD, not as an adult treatment; the manufacturer withdrew it from the U.S. market in 2008.
- Current supply: Compounding pharmacies (503A or 503B) are the only source of sermorelin acetate for clinical use.
- Mechanism: Stimulates endogenous GH release from anterior pituitary somatotrophs via the GHRH receptor; requires intact pituitary function to work at all.
- Evidence level: Low. Available adult studies are small, short-duration, and mostly conducted in healthy older adults rather than patients meeting formal adult GHD diagnostic criteria. No large randomized trial has evaluated sermorelin specifically in diagnosed adult GHD.
- Guideline status: Adult GHD management guidelines from endocrine professional societies center on recombinant human GH (somatropin); sermorelin is not a guideline-recommended therapy.
- Cost: Compounded sermorelin is rarely covered by insurance; readers should confirm current pricing directly with a compounding pharmacy rather than relying on a fixed figure, since prices vary by region and formulation and this figure has not been independently verified for this draft.
What sermorelin is, and why it differs from growth hormone itself
Sermorelin binds GHRH receptors on pituitary somatotrophs and prompts the pituitary to release its own GH in a pulsatile pattern, rather than delivering GH directly. This is the central conceptual difference from somatropin, which is recombinant GH itself and works regardless of pituitary function. The theoretical appeal of sermorelin is that it preserves the body's natural feedback loop: as GH and IGF-1 rise, hypothalamic somatostatin increases and GHRH signaling is dampened, which may reduce the chance of sustained supraphysiologic GH exposure compared with fixed-dose exogenous GH injections. This is a plausible pharmacologic mechanism, not a demonstrated clinical outcome advantage, because no adequately powered trial has compared long-term outcomes of sermorelin against somatropin in adults with confirmed GHD.
The practical consequence of this mechanism is that sermorelin's ceiling is set by how much functioning pituitary tissue remains. In adults whose GHD arises from pituitary surgery, cranial radiation, large tumors, or panhypopituitarism, somatotroph cells may be destroyed or severely damaged, and GHRH stimulation cannot produce meaningful GH release no matter the dose or duration.
FDA-approved indication versus off-label use: what patients should understand
The only FDA-approved use of sermorelin was as a diagnostic agent to help evaluate short stature in children, marketed as Geref Diagnostic. That approval has been inactive since the manufacturer discontinued the product in 2008 (see the FDA's application record for the original approval: FDA drug approval database, ApplNo 020604). There has never been an FDA-approved sermorelin product indicated for treating GHD in adults.
Physicians in the United States may legally prescribe an FDA-approved drug for a non-approved use based on clinical judgment. Sermorelin's situation is more unusual than typical off-label prescribing because the originally approved branded product no longer exists on the market. Everything currently prescribed is compounded, meaning it is prepared by a 503A pharmacy (compounding for an individual patient's prescription) or a 503B outsourcing facility (which compounds in batches under closer FDA oversight and current good manufacturing practice requirements). These two categories carry meaningfully different regulatory oversight, and the FDA's general compounding guidance explains the distinction: FDA, Compounding and the FDA: Questions and Answers.
Three points follow from this regulatory status, dated to this writing (2026) since compounding rules and bulk substance lists are subject to change:
- Insurance coverage for compounded sermorelin in adult GHD is uncommon, because the use is off-label and the product is compounded rather than FDA-approved.
- Potency, sterility, and purity depend on the individual compounding pharmacy's quality systems, not on a standardized manufacturing process reviewed by the FDA the way a branded drug would be.
- No phase III randomized controlled trial has evaluated sermorelin specifically as a treatment for adults with diagnosed GHD; the evidence base described below comes from smaller, older studies with different populations and endpoints.
What the evidence actually shows, and what it does not
The available published research on GHRH(1-29)/sermorelin in adults is limited in size, duration, and population. Several studies from the 1990s examined nightly or twice-daily GHRH(1-29) injections in healthy older adults, not in patients meeting formal adult GHD diagnostic criteria (a peak GH response below a defined threshold on provocative testing, in the appropriate clinical context). These studies generally reported increases in GH secretion and IGF-1 levels over treatment periods ranging from about two weeks to sixteen weeks, with some showing modest changes in body composition. Because the enrolled subjects were healthy elderly volunteers rather than diagnosed GHD patients, these results describe a GHRH pharmacology signal, not a validated treatment effect in the population this article is written for. Readers and clinicians should treat any specific percentage or magnitude drawn from these older trials as needing verification against the original journal articles before it is used to set expectations, since precise effect sizes were not independently confirmed for this draft.
By contrast, recombinant human GH (somatropin) has a substantially larger and more directly relevant evidence base in adult GHD, including multiple randomized, placebo-controlled trials that formed the basis of its FDA-approved adult GHD indications. Systematic reviews of this literature have generally found small but consistent improvements in body composition (reduced fat mass, increased lean mass) with somatropin therapy in adults with confirmed GHD, though effects on quality of life have been less consistent across studies. Adult GHD management guidelines published by endocrine professional societies reflect this evidence gap: they describe somatropin as the standard therapeutic approach for confirmed adult GHD and do not list GHRH analogs such as sermorelin among recommended therapies. The exact guideline citations should be verified directly against the current Endocrine Society and American Association of Clinical Endocrinologists publications before being used as a definitive reference, since specific document identifiers could not be confirmed for this draft.
Evidence boundary, stated plainly:
- Established: Sermorelin stimulates endogenous GH release via the GHRH receptor; this mechanism is well documented pharmacologically. Sermorelin's original, and only, FDA approval was as a pediatric diagnostic agent, now inactive.
- Plausible but unproven: That sermorelin produces clinically meaningful, durable improvements in body composition, energy, or quality of life in adults who meet formal GHD diagnostic criteria, comparable to somatropin. That preserving pulsatile GH secretion translates into a measurably better long-term safety profile than somatropin.
- Not established: Any specific magnitude of benefit in diagnosed adult GHD populations from a large randomized trial. Long-term safety of sermorelin in adult GHD over years of use. Superiority or equivalence to somatropin on any hard clinical endpoint.
Dosing patterns reported in off-label practice
The following reflects commonly reported off-label prescribing patterns for sermorelin in adult GHD, drawn from clinical practice descriptions rather than from a controlled trial or an approved label. It is not a guideline and it is not individualized dosing advice; any decision about starting dose, titration, or duration belongs to the prescribing clinician working directly with a specific patient's labs, symptoms, and comorbidities.
- Starting dose range commonly described: roughly 200 to 300 mcg subcutaneously once daily at bedtime, sometimes starting lower (around 100 mcg) in older patients or those with comorbidities, with upward titration over several weeks.
- Rationale for bedtime dosing: aligns with the body's natural nocturnal GH pulse; taking sermorelin close to a meal may blunt the GH response because postprandial insulin and glucose rises are known to suppress GH secretion.
- Titration target: IGF-1 within the age-adjusted normal range, generally aiming for the mid-to-upper portion of that range rather than the upper limit.
- Trial duration before reassessment: an initial 3-to-6-month trial is commonly described, with reassessment of IGF-1, symptoms, and (where used) body composition measures.
- Cycling protocols (periodic days or weeks off treatment, intended to reduce receptor desensitization) are described anecdotally in some clinical practice but have not been validated in a controlled trial; the rationale remains theoretical.
Because these patterns come from clinical practice description rather than a validated protocol, they should be treated as a starting point for a conversation with a prescriber, not as instructions to self-administer or self-titrate.
Monitoring: what should be checked, and when
Whatever specific protocol a clinician and patient agree on, baseline and follow-up labs are the backbone of responsible monitoring, because sermorelin's benefit (if any) can only be judged biochemically and clinically over time.
Before starting: IGF-1, comprehensive metabolic panel, fasting glucose or HbA1c, lipid panel, and thyroid function. GH signaling increases hepatic glucose output and can worsen insulin resistance, so glycemic monitoring matters particularly for patients with pre-diabetes or type 2 diabetes.
Early follow-up (commonly around 6 weeks): repeat IGF-1. If it has not moved meaningfully, adherence and injection technique should be reviewed before increasing the dose.
Mid-point follow-up (commonly around 12 weeks): repeat IGF-1, fasting glucose, and a clinical symptom review. This is typically the point at which a clinician and patient decide whether to continue, adjust, or stop.
Ongoing (every 3 to 6 months): IGF-1, metabolic panel, and clinical assessment. IGF-1 should not be pushed above the age-adjusted upper limit of normal; sustained supraphysiologic IGF-1 has been associated with increased risk in some cancer epidemiology literature, which is a reason to titrate to the normal range rather than to a maximal response.
Reported side effects of sermorelin in the available literature are mostly mild: injection site reactions, transient flushing, headache, and dizziness. Because the underlying studies are small, they cannot rule out rarer or longer-term risks, and this should be stated to patients directly rather than implied away.
A separate and practical safety issue is product quality. Compounded sterile preparations are not subject to the same batch-by-batch FDA review as approved drugs, and quality problems (potency variability, contamination) have been a documented concern in compounding generally, per the FDA's own compounding guidance referenced above. Prescribers and patients should ask any compounding pharmacy for current certificates of analysis and evidence of third-party potency and sterility testing rather than assuming quality by default.
Who is a reasonable candidate, and who is not
The single most important selection factor is whether the patient has residual, functioning pituitary somatotroph tissue.
Potentially reasonable candidates: adults with a documented subnormal GH response on provocative testing whose pituitary is structurally intact on imaging, and who have not had pituitary surgery, radiation, or a large destructive lesion. These patients may retain enough somatotroph capacity to respond to GHRH stimulation, though even here the response cannot be predicted with certainty from imaging alone.
Poor candidates: adults whose GHD results from pituitary surgery, cranial radiation, large sellar or suprasellar tumors, or panhypopituitarism. In these cases the somatotroph cells are typically destroyed or severely compromised, and GHRH stimulation is unlikely to produce a meaningful GH response regardless of dose. Guideline-based care for these patients is somatropin, evaluated individually by an endocrinologist.
A patient's original diagnostic GHRH stimulation test result (if one was used to diagnose GHD) can offer a rough signal here: a very low peak GH response to a diagnostic GHRH dose suggests limited somatotroph reserve and a lower likelihood that chronic sermorelin therapy will produce a measurable effect. This is a clinical judgment made by the prescribing endocrinologist, not a rule a patient can apply to themselves.
Clinician-conversation and monitoring framework
This framework aims to organize discussions between patients and physicians regarding sermorelin use, clarifying the boundary between general educational content and personalized clinical decision-making. It should not be construed as a treatment protocol and cannot substitute for an endocrinologist's individual evaluation.
Before starting sermorelin, the conversation should establish:
| Question | Why it matters | Where the boundary sits |
|---|---|---|
| What caused this GHD diagnosis? | Determines whether somatotroph cells are likely intact (idiopathic/age-related) or destroyed (surgery, radiation, large tumor) | Clinical judgment based on imaging and history, not general information |
| What was the peak GH on provocative testing? | A very low peak suggests limited reserve and lower odds of response to GHRH stimulation | Individualized interpretation by the ordering endocrinologist |
| Why sermorelin instead of somatropin? | Somatropin is the guideline-recommended standard; the rationale for deviating should be documented | Site- and patient-specific judgment, informed consent |
| What is the compounding pharmacy's quality assurance? | Compounded products are not FDA-reviewed batch by batch | General verification step any patient/clinician can do |
| What defines success, and by when? | Prevents indefinite use without evidence of benefit | Should be set explicitly at baseline, not inferred later |
Checkpoints and stop/escalation conditions during treatment:
- ~6 weeks: IGF-1 recheck. No meaningful change and good adherence should prompt a dose or technique review, not automatic escalation.
- ~12 weeks: IGF-1, fasting glucose, and a structured symptom review. If IGF-1 remains in the lower third of the age-adjusted normal range despite an adequate trial dose, this is a reasonable point to discuss transitioning to somatropin rather than continuing sermorelin indefinitely.
- New or worsening hyperglycemia: GH-axis stimulation can worsen insulin resistance; escalating glucose values warrant reassessment of whether to continue, particularly in patients with pre-diabetes or diabetes.
- IGF-1 above the age-adjusted upper limit of normal: warrants a dose reduction, not a decision to "push through" for more effect.
- No measurable IGF-1 or symptom change by 3 to 6 months: a reasonable point to stop and reconsider the original diagnosis, the compounding pharmacy's product quality, or a switch to guideline-based somatropin therapy.
- New neurological symptoms, visual changes, or signs suggesting pituitary tumor growth: this is outside the scope of routine peptide monitoring and warrants urgent evaluation by the treating endocrinologist or urgent care, not adjustment of the sermorelin dose.
What this framework cannot do: it cannot tell an individual patient what dose to take, whether they are a biological responder, or when their personal risk-benefit balance favors stopping. Those judgments require an endocrinologist who has the patient's imaging, stimulation test results, and full medical history.
Sermorelin versus somatropin: how they actually differ
| Sermorelin (off-label) | Somatropin (FDA-approved for adult GHD) | |
|---|---|---|
| FDA status in adult GHD | Not approved; off-label, compounded only | Multiple FDA-approved products with adult GHD indications |
| Evidence base | Small, mostly short-duration studies, largely in healthy older adults rather than diagnosed GHD patients | Multiple randomized controlled trials and systematic reviews in diagnosed adult GHD populations |
| Requires intact pituitary function | Yes, this is a hard biological requirement | No, delivers GH directly regardless of pituitary status |
| Guideline recommendation | Not listed as a recommended therapy in adult GHD guidelines | Standard of care per endocrine society guidelines |
| Long-term safety data | Not established in adult GHD | Decades of post-marketing surveillance in treated adult GHD populations |
| Typical monthly cost | Lower, but rarely insurance-covered | Higher, but sometimes offset by manufacturer patient assistance programs |
| Administration | Daily subcutaneous injection | Daily subcutaneous injection; some newer formulations offer weekly dosing |
The theoretical advantage claimed for sermorelin, preserved pulsatile secretion and intact negative feedback, is biologically plausible but has not been shown in a head-to-head trial to produce better clinical outcomes than somatropin. Readers should not interpret the theoretical mechanism as proof of a real-world safety or efficacy advantage.
Regulatory and legal considerations
Prescribing compounded sermorelin off-label is legal in the United States, but the framework differs from prescribing an FDA-approved drug off-label in one important way: the original branded, FDA-approved sermorelin product no longer exists, so there is no manufacturer-controlled supply chain to fall back on. All current product comes from 503A pharmacies (compounding to a patient-specific prescription) or 503B outsourcing facilities (which compound in batch under closer FDA oversight, including registration and current good manufacturing practice requirements). The FDA maintains lists of bulk substances that may be used in compounding, and a substance's status on those lists can change; anyone relying on sermorelin's current regulatory standing should check the FDA's compounding resources directly rather than assume the status described in this article remains current indefinitely (see FDA, Compounding and the FDA: Questions and Answers).
State pharmacy boards may add further restrictions on peptide compounding beyond federal rules. From a documentation standpoint, off-label prescribing generally carries more medicolegal exposure than on-label prescribing, and clinicians who choose sermorelin over somatropin should document their clinical rationale, informed consent covering the off-label status and limited evidence base, and objective monitoring data showing (or failing to show) treatment response.
Practical notes for patients
Sermorelin is typically supplied as a lyophilized powder that must be reconstituted with bacteriostatic water, refrigerated, and used within the timeframe specified by the compounding pharmacy, commonly around 28 to 30 days. Administering it 30 to 60 minutes before sleep on an empty stomach is the commonly described approach, because eating shortly before or after injection can blunt the GH response through insulin-mediated suppression.
Patients should expect a gradual, modest response if sermorelin works at all: measurable IGF-1 changes, when they occur, typically take several weeks, and any body composition change takes months. Claims of rapid, dramatic transformation from sermorelin are not supported by the evidence described above and should be treated skeptically regardless of where they are made.
When to seek urgent care rather than adjust a peptide dose
New visual field changes, severe headache, signs of a pituitary mass effect, or any acute neurological symptom should prompt urgent medical evaluation, not a change to a sermorelin regimen. Similarly, uncontrolled hyperglycemia or symptoms of a diabetic emergency require urgent care rather than a wait for the next scheduled lab check.
Frequently asked questions
Is sermorelin FDA-approved for adult growth hormone deficiency? No. Its only FDA approval was as a diagnostic agent for pediatric GHD, and that branded product was discontinued in 2008. All adult therapeutic use is off-label and relies on compounded preparations.
How does sermorelin differ from growth hormone (somatropin) itself? Sermorelin stimulates the pituitary to release the body's own GH and requires functioning somatotroph cells to work. Somatropin is GH itself, delivered directly, and works regardless of pituitary function.
Who is unlikely to respond to sermorelin? Adults whose GHD comes from pituitary surgery, cranial radiation, a large sellar tumor, or panhypopituitarism are unlikely to respond, because their somatotroph cells are typically too damaged for GHRH stimulation to produce meaningful GH release.
Is sermorelin safer than injected growth hormone? It may carry a theoretical advantage because it works through the body's own feedback loop, but this has not been demonstrated in a controlled comparison, and somatropin has a much larger long-term safety record in diagnosed adult GHD. A confident safety comparison is not currently possible from the available evidence.
Does insurance cover compounded sermorelin for adult GHD? Coverage is uncommon because the use is off-label and the product is compounded rather than FDA-approved. Patients should confirm current costs directly with a compounding pharmacy.
What should be monitored during treatment? At minimum, IGF-1 at baseline and at intervals during treatment, along with fasting glucose or HbA1c, a metabolic panel, lipid panel, and thyroid function, with the schedule set by the prescribing clinician.
What if IGF-1 does not rise on treatment? A patient who shows no meaningful IGF-1 change after an adequate trial period likely has insufficient somatotroph reserve to benefit from sermorelin, and a conversation with an endocrinologist about somatropin is a reasonable next step.
References
- U.S. Food and Drug Administration. Geref Diagnostic (sermorelin acetate for injection) approval record. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020604
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Note for editorial and medical review: specific journal citations for the adult and elderly GHRH(1-29) studies, the somatropin RCTs, the systematic review figures, and the compounding quality statistic referenced in earlier drafts of this article could not be independently verified against the primary literature during this revision and have been described in general, hedged terms rather than attributed to specific papers. Before publication, these claims should be checked against PubMed and current Endocrine Society/AACE guideline documents and either restored with a verified citation or left in their current general form.